Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
91-105 of 3711 results
Omeros gets FDA clearance for IND application of thrombotic microangiopathies drug
By PBR Staff Writer
US-based biopharmaceutical Omeros has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug application (IND) to assess its lead human monoclonal antibody OMS721 for the inhibition of complement-mediated thrombotic microangiopathies (TMAs).
Drug Research > Drug Discovery & Development > News
Sun Pharma to acquire Ranbaxy Laboratories for $3.2bn
By PBR Staff Writer
Sun Pharmaceutical has entered into definitive agreement to acquire Ranbaxy Laboratories in an all-stock transaction totalling equity value of $3.2bn.
Drug Research > Drug Discovery & Development > News
AMRI completes acquisition of Cedarburg Pharmaceuticals
Albany Molecular Research (AMRI) has announced that it has completed the previously announced acquisition of Cedarburg Pharmaceuticals.
Drug Research > Drug Discovery & Development > News
FDA accepts filing of The Medicines Company's US biologic license application for fibrocaps hemostatic agent
The Medicines Company has announced that the US Food and Drug Administration (FDA) has accepted the filing of a biologic license application (BLA) for the investigational hemostatic agent Fibrocaps, a dry powder formulation of fibrinogen and thrombin being developed to aid in hemostasis during surgery, where control of mild or moderate bleeding by conventional means is ineffective or impractical.
Drug Research > Drug Discovery & Development > News
Particle Sciences enters into joint development agreement with Actavis
Particle Sciences, a drug delivery Contract Development and Manufacturing Organization (CDMO), has entered into an exclusive agreement with Actavis (ACT), a specialty pharmaceutical company, to develop an unnamed complex generic product.
Drug Research > Drug Discovery & Development > News
AstraZeneca, MRC enter into new drug discovery collaboration
By PBR Staff Writer
AstraZeneca has entered into a strategic collaboration with the UK Medical Research Council (MRC) to create a new center for early drug discovery in Cambridge, UK.
Drug Research > Drug Discovery & Development > News
Cilian and University of Edinburgh develop Malaria vaccine
In collaboration with the University of Edinburgh in Scotland, the biotechnology firm Cilian succeeded to reconstruct an important surface protein of the Malaria parasite.
Drug Research > Drug Discovery & Development > News
Pulmokine receives $1.5m Stage B VITA contract from NHLBI
Pulmokine announced it has been awarded a Stage B Vascular Interventions and Therapeutic Advances (VITA) contract from the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH).
Drug Research > Drug Discovery & Development > News
Xenon, Genentech to develop new therapeutic targets for treating pain
By PBR Staff Writer
Canada-based Xenon Pharmaceuticals has entered into a new collaboration with Genentech, a member of the Roche Group, to discover and validate new therapeutic targets and mechanisms for treating pain.
Drug Research > Drug Discovery & Development > News
Adaptimmune receives £2.1m grant from Biomedical Catalyst Fund
By PBR Staff Writer
Adaptimmune has received £2.1m grant from the Biomedical Catalyst Fund to advance the development of company’s second engineered T cell therapy program into the clinic in triple negative breast cancer.
Drug Research > Drug Discovery & Development > News
Antisense Therapeutics reports completion of patient enrollment in Phase II trial of ATL1103
Antisense Therapeutics has reported that 24 acromegalic patients have been successfully enrolled and randomized to one of the two treatment regimens of dosing in the Phase II trial of ATL1103 for the growth disorder, acromegaly.
Drug Research > Drug Discovery & Development > News
Medivir’s Simeprevir receives positive CHMP opinion in EU for treatment of chronic hepatitis C
Medivir has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorization in the EU for the use of simeprevir in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients.
Drug Research > Drug Discovery & Development > News
Eisai partners with LSTM and UoL to discover new anti-filarial drugs
By PBR Staff Writer
Japanese pharmaceutical firm Eisai has entered a collaboration with the Liverpool School of Tropical Medicine (LSTM) and University of Liverpool (UoL) to jointly discover new drugs effective against lymphatic filariasis and onchocerciasis (river blindness), both major types of filariasis.
Drug Research > Drug Discovery & Development > News
Sanofi, SK Chemical to develop new pneumococcal conjugate vaccine
By PBR Staff Writer
Sanofi's vaccines division Sanofi Pasteur and South Korea-based SK Chemicals have entered into a long-term strategic cooperation to jointly develop a new pneumococcal conjugate vaccine (PCV).
Drug Research > Drug Discovery & Development > News
GenSpera announces enrollment of first patient in GenSpera G-202 Phase II glioblastoma trial
GenSpera has announced that the first patient was enrolled in the Phase II clinical trial of its lead compound, G-202, in patients who have glioblastoma multiforme (GBM), the most prevalent type of primary brain cancer.
Drug Research > Drug Discovery & Development > News
91-105 of 3711 results